This site is intended for healthcare professionals
Latest industry news
  • Home
  • /
  • News
  • /
  • 2024
  • /
  • 4
  • /
  • Vertex acquires Alpine Immune Sciences and with it...
News

Vertex acquires Alpine Immune Sciences and with it povetacicept, a potential treatment for kidney disease.

Read time: 1 mins
Published:11th Apr 2024

Vertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc. a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash

The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close later this quarter. Alpine’s lead molecule, povetacicept (ALPN-303), is a highly potent and effective dual antagonist of BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand). Through Phase II development, povetacicept has shown potential best-in-class efficacy in IgA nephropathy (IgAN). IgAN is a serious, progressive, autoimmune disease of the kidney that can lead to end-stage-renal disease. There are no approved therapies that target the underlying cause of IgAN. IgAN is the most common cause of primary (idiopathic) glomerulonephritis worldwide, affecting approximately 130,000 people in the U.S. Povetacicept is on track to enter Phase III clinical development in the second half of 2024. Due to its mechanism of action as a dual BAFF/APRIL antagonist, povetacicept holds the potential to benefit patients with other serious autoimmune diseases of the kidney, such as membranous nephropathy and lupus nephritis, as well as autoimmune cytopenias. Clinical studies in renal indications and autoimmune cytopenias are ongoing.

Type: industry

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.